Buprenorphine - Faran Shirin
Latest Information Update: 28 Apr 2022
At a glance
- Originator Faran Shimi
- Developer Faran Shimi; Tehran University of Medical Sciences
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Opioid-related disorders; Pain; Substance-related disorders
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for research development in Opioid-related-disorders in Iran (Sublingual, Tablet)
- 28 Apr 2022 No recent reports of development identified for research development in Pain in Iran (Sublingual, Tablet)
- 30 Mar 2021 No development reported - Phase-II for Substance-related disorders in Iran (Sublingual)